Acarbose vs Canagliflozin
Two approved diabetes drugs cleared the same NIA mouse longevity bar with the same male-only pattern — the choice between them, taken off-label for aging, comes down to side-effect profile, not the mouse data.
Short answer
Acarbose and canagliflozin are both marketed for type 2 diabetes and both have approval-level evidence, so the difference is in how they work and what their trials found. Acarbose reduced progression from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial; no human lifespan trials. Both are prescription drugs.
Acarbose
Precose
FDA-approved alpha-glucosidase inhibitor for diabetes, with a repeated, male-skewed median-lifespan extension in the NIA ITP mouse program — the same pattern later seen with canagliflozin. No human longevity trial exists; taking it off-label for aging means acting ahead of the evidence, not on it.
Full Acarbose evidence reviewCanagliflozin
Invokana
FDA-approved SGLT2 inhibitor with real cardiovascular and renal outcome trials (CANVAS, CREDENCE) — but the longevity claim rests entirely on a 14% median-lifespan extension in male-only NIA ITP mice; no human longevity trial exists, and the drug carries real risks (amputation, Fournier's gangrene, euglycemic DKA) that apply the same whether it's prescribed for diabetes or taken off-label for aging.
Full Canagliflozin evidence reviewAcarbose vs Canagliflozin: head to head
- FDA status / approved use
Acarbose
FDA-approved for type 2 diabetes; not approved or proven for longevityCanagliflozin
FDA-approved (Invokana) for type 2 diabetes; longevity use is off-label and untested in humans- Marketed for
Acarbose
Type 2 diabetes (approved); explored for longevity via NIA ITP mouse dataCanagliflozin
Type 2 diabetes (approved); explored off-label for longevity on mouse ITP data- Outcome areas
Acarbose
Blood sugar / insulin sensitivity; Longevity / lifespanCanagliflozin
Blood sugar / insulin sensitivity; Cardiovascular; Longevity / lifespan- Evidence grade
Acarbose
FDA-approvedCanagliflozin
FDA-approved- How it works
Acarbose
Slows gut enzymes that break starch into glucose, blunting post-meal blood sugarCanagliflozin
Blocks the kidney's SGLT2 transporter so glucose leaves the body in urine- Route and dosing
Acarbose
Oral, taken with the first bite of a mealCanagliflozin
Oral tablet, prescription only- Headline human result
Acarbose
Reduced progression from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial; no human lifespan trialsCanagliflozin
Major cardiovascular events cut, hazard ratio 0.86 vs placebo, in the CANVAS Program of about 10,000 people with type 2 diabetes- Strongest evidence
Acarbose
Harrison 2014 NIA ITP, Aging CellAcarbose evidence reviewPubMed 24245565Canagliflozin
Miller 2020 NIA ITP, JCI InsightCanagliflozin evidence reviewPubMed 32990681- Key safety signal
Acarbose
Flatulence and diarrhea are common and dose-related, the usual reason people stopCanagliflozin
Ketoacidosis, genital infections, Fournier's gangrene, volume depletion and raised lower-limb amputation risk- How it is obtained
Acarbose
Prescription drugCanagliflozin
Prescription drug
| Acarbose | Canagliflozin | |
|---|---|---|
| FDA status / approved use | FDA-approved for type 2 diabetes; not approved or proven for longevity | FDA-approved (Invokana) for type 2 diabetes; longevity use is off-label and untested in humans |
| Marketed for | Type 2 diabetes (approved); explored for longevity via NIA ITP mouse data | Type 2 diabetes (approved); explored off-label for longevity on mouse ITP data |
| Outcome areas | Blood sugar / insulin sensitivity; Longevity / lifespan | Blood sugar / insulin sensitivity; Cardiovascular; Longevity / lifespan |
| Evidence grade | FDA-approved | FDA-approved |
| How it works | Slows gut enzymes that break starch into glucose, blunting post-meal blood sugar | Blocks the kidney's SGLT2 transporter so glucose leaves the body in urine |
| Route and dosing | Oral, taken with the first bite of a meal | Oral tablet, prescription only |
| Headline human result | Reduced progression from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial; no human lifespan trials | Major cardiovascular events cut, hazard ratio 0.86 vs placebo, in the CANVAS Program of about 10,000 people with type 2 diabetes |
| Strongest evidence | Harrison 2014 NIA ITP, Aging CellAcarbose evidence reviewPubMed 24245565 | Miller 2020 NIA ITP, JCI InsightCanagliflozin evidence reviewPubMed 32990681 |
| Key safety signal | Flatulence and diarrhea are common and dose-related, the usual reason people stop | Ketoacidosis, genital infections, Fournier's gangrene, volume depletion and raised lower-limb amputation risk |
| How it is obtained | Prescription drug | Prescription drug |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- FDA-approved:
- Approved by the FDA for a defined indication, on the strength of pivotal human trials.
Our verdict
Both extended median lifespan in the NIA Interventions Testing Program, repeatably, and both showed the effect mostly or entirely in male mice — a genuine, unexplained puzzle, not a reason to prefer one over the other. Where they differ is the human safety record: acarbose's main issue is GI tolerability (gas, bloating), while canagliflozin carries real risks — amputation, Fournier's gangrene, euglycemic DKA — with no acarbose equivalent. Neither has a human longevity trial; both remain hypotheses borrowed from mice.
Acarbose fits if
You want the milder, GI-side-effect-only safety profile, and you can tolerate the digestive adjustment period.
Canagliflozin fits if
You have (or are managing) type 2 diabetes already and canagliflozin is a legitimate part of that regimen — using it off-label purely for the mouse longevity signal is a different, harder-to-justify decision given its more serious risk profile.
Acarbose vs Canagliflozin: common questions
- Are acarbose and canagliflozin both FDA-approved?
- Yes. Acarbose is FDA-approved for type 2 diabetes; not approved or proven for longevity. Canagliflozin is FDA-approved (Invokana) for type 2 diabetes; longevity use is off-label and untested in humans.
- Which has stronger human evidence, acarbose or canagliflozin?
- Neither clearly. Both have approval-level evidence. The key source for acarbose is Harrison 2014 NIA ITP, Aging Cell; for canagliflozin, it is Miller 2020 NIA ITP, JCI Insight.
- What are the main safety concerns with acarbose and canagliflozin?
- With acarbose, flatulence and diarrhea are common and dose-related, the usual reason people stop. For canagliflozin, watch for ketoacidosis, genital infections, Fournier's gangrene, volume depletion and raised lower-limb amputation risk.
Key studies behind each
Acarbose
- Harrison DE, Strong R, Allison DB, et al. (2014). Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell. PubMed 24245565
- Harrison DE, Strong R, Alavez S, et al. (2019). Acarbose improves health and lifespan in aging HET3 mice. Aging Cell. PubMed 30688027
- Chiasson JL, Josse RG, Gomis R, et al. (2002). Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. PubMed 12086760
- Holman RR, Coleman RL, Chan JCN, et al. (2017). Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. PubMed 28917545
Canagliflozin
- Miller RA, Harrison DE, Allison DB, et al. (2020). Canagliflozin extends life span in genetically heterogeneous male but not female mice. JCI Insight. PubMed 32990681
- Jayarathne HSM, Debarba LK, Jaboro JJ, Ginsburg BC, Miller RA, Sadagurski M. (2022). Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM-HET3 mice. Aging Cell. PubMed 35707855
- Neal B, Perkovic V, Mahaffey KW, et al. (2017). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS Program). N Engl J Med. PubMed 28605608
- Perkovic V, Jardine MJ, Neal B, et al. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE). N Engl J Med. PubMed 30990260
The full evidence reviews
- Acarbose and longevity: a carb-blocker with a real mouse-lifespan signal
An approved diabetes drug that repeatably extended lifespan in NIA mice — more in males. A straight read of the mouse data, the human gap, and the side-effect ceiling.
Updated August 2026
- Canagliflozin and longevity: a diabetes drug with a male-only mouse-lifespan signal
An approved SGLT2 inhibitor that extended median lifespan 14% in male NIA mice, with no benefit in females — a prescriber decision, not a supplement purchase.
Updated August 2026